Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > BROWSE ARTICLES > Author index
Search
Eun-Seok Kang  (Kang ES) 1 Article
Obesity and Metabolism
Optimal Candidates for the Switch from Glimepiride to Sitagliptin to Reduce Hypoglycemia in Patients with Type 2 Diabetes Mellitus
Hyun Min Kim, Jung Soo Lim, Byung-Wan Lee, Eun-Seok Kang, Hyun Chul Lee, Bong-Soo Cha
Endocrinol Metab. 2015;30(1):84-91.   Published online March 27, 2015
DOI: https://doi.org/10.3803/EnM.2015.30.1.84
  • 5,524 View
  • 91 Download
  • 12 Web of Science
  • 11 Crossref
AbstractAbstract PDFPubReader   
Background

Sitagliptin is a novel antidiabetic agent with a low risk for hypoglycemia. We investigated the efficacy and safety of sitagliptin when patients switched from a sulfonylurea to sitagliptin and identified good candidates for the switch.

Methods

Sixty-one patients with type 2 diabetes switched from glimepiride with metformin to sitagliptin with metformin due to clinical hypoglycemia. Serum glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), and 2-hour postprandial plasma glucose (2h-PPG) before and 12 and 24 weeks after the drug switch were checked.

Results

HbA1c and FPG levels did not change 12 or 24 weeks after the switch; however, the 2h-PPG level decreased from 218.0±67.5 mg/dL at baseline to 197.1±69.9 mg/dL at 12 weeks and 192.3±67.4 mg/dL at 24 weeks after switching drugs (P=0.045, P=0.018, respectively). All but one patient no longer experienced hypoglycemia after discontinuing glimepiride. In a multivariate logistic regression analysis, a high homeostasis model assessment of insulin resistance and low baseline HbA1c level were independent predictors of an HbA1c ≤7% after switching to sitagliptin.

Conclusion

Glycemic control was not aggravated in patients 24 weeks after the drug switch, and symptomatic hypoglycemia decreased significantly. Patients with dominant insulin resistance may be good candidates for switching from a sulfonylurea to sitagliptin to reduce hypoglycemia.

Citations

Citations to this article as recorded by  
  • Application of Machine Learning Methods for the Development of Antidiabetic Drugs
    Juanjuan Zhao, Pengcheng Xu, Xiujuan Liu, Xiaobo Ji, Minjie Li, Dev Sooranna, Xiaosheng Qu, Wencong Lu, Bing Niu
    Current Pharmaceutical Design.2022; 28(4): 260.     CrossRef
  • Efficacy and safety of dorzagliatin for type 2 diabetes mellitus: A meta-analysis and trial sequential analysis
    Yunfeng Yu, Xingyu Yang, Keke Tong, Shuang Yin, Gang Hu, Fei Zhang, Pengfei Jiang, Manli Zhou, Weixiong Jian
    Frontiers in Cardiovascular Medicine.2022;[Epub]     CrossRef
  • Factors associated with switching from sulphonylureas to dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in the United States
    Xi Tan, Lingfeng Yang, Kamlesh Khunti, Ruya Zhang, Ye Zhang, Swapnil Rajpathak, Miao Yu
    Diabetes, Obesity and Metabolism.2021; 23(10): 2251.     CrossRef
  • Increased risk of adverse cardiovascular events by strict glycemic control after percutaneous coronary intervention (HbA1c < 6.5% at 2 years) in type 2 diabetes mellitus combined with acute coronary syndrome: a 5-years follow-up study
    Tiangui Yang, Peng Fu, Jie Chen, Xi Fu, Changlu Xu, Xiaoxia Liu, Tiesheng Niu
    Current Medical Research and Opinion.2021; 37(9): 1517.     CrossRef
  • Clinical analysis of pre-existing diabetes mellitus and dipeptidyl peptidase-4 inhibitors in patients with remitting seronegative symmetrical synovitis and pitting edema syndrome
    Yoshiro Horai, Tomoki Origuchi, Nozomi Iwanaga, Junichi Tokumitsu, Toshiyuki Ikeoka, Genpei Kuriya, Yasumori Izumi, Atsushi Kawakami
    Modern Rheumatology.2020; 30(4): 703.     CrossRef
  • The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials
    Juan Ling, Peng Cheng, Long Ge, Ding-hua Zhang, An-chen Shi, Jin-hui Tian, Ya-jing Chen, Xiu-xia Li, Jing-yun Zhang, Ke-hu Yang
    Acta Diabetologica.2019; 56(3): 249.     CrossRef
  • Satisfaction and efficacy of switching from daily dipeptidyl peptidase-4 inhibitors to weekly trelagliptin in patients with type 2 diabetes—Randomized controlled study—
    Mayuko Oita, Hideaki Miyoshi, Kota Ono, Akinobu Nakamura, Kyu Yong Cho, Hiroshi Nomoto, Kohei Yamamoto, Kazuno Omori, Naoki Manda, Yoshio Kurihara, Shin Aoki, Tatsuya Atsumi
    Endocrine Journal.2018; 65(2): 141.     CrossRef
  • Efficacy and safety of evogliptin versus sitagliptin as add on to metformin alone in a combined russian-korean population. Evo-combi trial
    Alina Y. Babenko, Anna A. Mosikian, Igor E. Makarenko, Victoriya V. Leusheva, Evgeny V. Shlyakhto
    Diabetes mellitus.2018; 21(4): 241.     CrossRef
  • Effectiveness prediction of Evogliptin treatment in type 2 diabetes mellitus in russian-korean population
    Anna A. Mosikian, Alina Y. Babenko, Yulia A. Sevastyanova, Roman V. Drai, Evgenij V. Shlyakhto
    Diabetes mellitus.2018; 21(5): 333.     CrossRef
  • Comprehensive analysis of the Co-structures of dipeptidyl peptidase IV and its inhibitor
    Hiroyuki Nojima, Kazuhiko Kanou, Genki Terashi, Mayuko Takeda-Shitaka, Gaku Inoue, Koichiro Atsuda, Chihiro Itoh, Chie Iguchi, Hajime Matsubara
    BMC Structural Biology.2016;[Epub]     CrossRef
  • A genetic variant in GLP1R is associated with response to DPP-4 inhibitors in patients with type 2 diabetes
    Eugene Han, Hye Sun Park, Obin Kwon, Eun Yeong Choe, Hye Jin Wang, Yong-ho Lee, Sang-Hak Lee, Chul Hoon Kim, Lee-Kyung Kim, Soo Heon Kwak, Kyong Soo Park, Chul Sik Kim, Eun Seok Kang
    Medicine.2016; 95(44): e5155.     CrossRef
Close layer

Endocrinol Metab : Endocrinology and Metabolism